APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Amyotrophic Lateral Sclerosis (ALS) Industry Research Report 2026

Report ID 173963210520 December 2025117 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Amyotrophic Lateral Sclerosis (ALS) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Amyotrophic Lateral Sclerosis (ALS) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Amyotrophic Lateral Sclerosis (ALS) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Amyotrophic Lateral Sclerosis (ALS) include Sun Pharma, Sanofi, Lunan Pharma, Mylan Pharma, Mitsubishi Tanabe Pharma, Glemark Generics, Covis Pharma and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Amyotrophic Lateral Sclerosis (ALS) market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Amyotrophic Lateral Sclerosis (ALS) Market by Company

Sun Pharma

Sanofi

Lunan Pharma

Mylan Pharma

Mitsubishi Tanabe Pharma

Glemark Generics

Covis Pharma

Apotex

Amyotrophic Lateral Sclerosis (ALS) Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Amyotrophic Lateral Sclerosis (ALS) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Amyotrophic Lateral Sclerosis (ALS) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales (k units) of Manufacturers (2021-2026) Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Revenue of Manufacturers (2021-2026) Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Amyotrophic Lateral Sclerosis (ALS) Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Type & Application Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Amyotrophic Lateral Sclerosis (ALS) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sun Pharma Company Information Table 19. Sun Pharma Business Overview Table 20. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 22. Sun Pharma Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 27. Sanofi Recent Developments Table 28. Lunan Pharma Company Information Table 29. Lunan Pharma Business Overview Table 30. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 32. Lunan Pharma Recent Developments Table 33. Mylan Pharma Company Information Table 34. Mylan Pharma Business Overview Table 35. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 37. Mylan Pharma Recent Developments Table 38. Mitsubishi Tanabe Pharma Company Information Table 39. Mitsubishi Tanabe Pharma Business Overview Table 40. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 42. Mitsubishi Tanabe Pharma Recent Developments Table 43. Glemark Generics Company Information Table 44. Glemark Generics Business Overview Table 45. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 47. Glemark Generics Recent Developments Table 48. Covis Pharma Company Information Table 49. Covis Pharma Business Overview Table 50. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 52. Covis Pharma Recent Developments Table 53. Apotex Company Information Table 54. Apotex Business Overview Table 55. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 57. Apotex Recent Developments Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026) & (k units) Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2021-2026) Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032) & (k units) Table 62. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2027-2032) Table 63. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2021-2026) Table 65. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2027-2032) Table 67. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 69. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 70. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 74. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 75. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 79. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 80. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 84. South America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 85. South America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 89. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 90. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 93. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 94. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2026) Table 95. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2027-2032) Table 96. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2026) Table 99. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2027-2032) Table 100. Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2026) & (US$/unit) Table 101. Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2027-2032) & (US$/unit) Table 102. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 103. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 104. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2026) Table 105. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2027-2032) Table 106. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2026) Table 109. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2027-2032) Table 110. Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2026) & (US$/unit) Table 111. Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2027-2032) & (US$/unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Amyotrophic Lateral Sclerosis (ALS) Distributors List Table 115. Amyotrophic Lateral Sclerosis (ALS) Customers List Table 116. Amyotrophic Lateral Sclerosis (ALS) Industry Trends Table 117. Amyotrophic Lateral Sclerosis (ALS) Industry Drivers Table 118. Amyotrophic Lateral Sclerosis (ALS) Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Amyotrophic Lateral Sclerosis (ALS) Product Image Figure 5. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Market Size (2021-2032) & (US$ Million) Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2032) & (k units) Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Average Price (US$/unit) & (2021-2032) Figure 9. Riluzole Product Image Figure 10. Edaravone (Radicava) Product Image Figure 11. Other Product Image Figure 12. Hospital Product Image Figure 13. Drugs Store Product Image Figure 14. Other Product Image Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region in 2025 Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region in 2025 Figure 22. North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country in 2025 Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 24. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2021-2032) Figure 25. United States Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country in 2025 Figure 29. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 30. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2021-2032) Figure 31. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country in 2025 Figure 42. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2021-2032) Figure 44. China Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country in 2025 Figure 53. South America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 54. South America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2021-2032) Figure 55. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country in 2025 Figure 59. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2021-2032) Figure 61. Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2032) Figure 67. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2032) Figure 68. Global Amyotrophic Lateral Sclerosis (ALS) Price (US$/unit) by Type (2021-2032) Figure 69. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2032) Figure 70. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2032) Figure 71. Global Amyotrophic Lateral Sclerosis (ALS) Price (US$/unit) by Application (2021-2032) Figure 72. Amyotrophic Lateral Sclerosis (ALS) Value Chain Figure 73. Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Sun Pharma
  • Sanofi
  • Lunan Pharma
  • Mylan Pharma
  • Mitsubishi Tanabe Pharma
  • Glemark Generics
  • Covis Pharma
  • Apotex

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size (2021-2032)
  4. 2.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2032)
  5. 2.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Market Average Price (2021-2032)
  6. 2.3 Amyotrophic Lateral Sclerosis (ALS) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Riluzole
  9. 2.3.3 Edaravone (Radicava)
  10. 2.3.4 Other
  11. 2.4 Amyotrophic Lateral Sclerosis (ALS) by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital
  14. 2.4.3 Drugs Store
  15. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Amyotrophic Lateral Sclerosis (ALS) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Type & Application
  8. 3.8 Global Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Established Date
  9. 3.9 Global Amyotrophic Lateral Sclerosis (ALS) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sun Pharma
  2. 4.1.1 Sun Pharma Company Information
  3. 4.1.2 Sun Pharma Business Overview
  4. 4.1.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  6. 4.1.5 Sun Pharma Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Lunan Pharma
  14. 4.3.1 Lunan Pharma Company Information
  15. 4.3.2 Lunan Pharma Business Overview
  16. 4.3.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  18. 4.3.5 Lunan Pharma Recent Developments
  19. 4.4 Mylan Pharma
  20. 4.4.1 Mylan Pharma Company Information
  21. 4.4.2 Mylan Pharma Business Overview
  22. 4.4.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  24. 4.4.5 Mylan Pharma Recent Developments
  25. 4.5 Mitsubishi Tanabe Pharma
  26. 4.5.1 Mitsubishi Tanabe Pharma Company Information
  27. 4.5.2 Mitsubishi Tanabe Pharma Business Overview
  28. 4.5.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  30. 4.5.5 Mitsubishi Tanabe Pharma Recent Developments
  31. 4.6 Glemark Generics
  32. 4.6.1 Glemark Generics Company Information
  33. 4.6.2 Glemark Generics Business Overview
  34. 4.6.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  36. 4.6.5 Glemark Generics Recent Developments
  37. 4.7 Covis Pharma
  38. 4.7.1 Covis Pharma Company Information
  39. 4.7.2 Covis Pharma Business Overview
  40. 4.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  42. 4.7.5 Covis Pharma Recent Developments
  43. 4.8 Apotex
  44. 4.8.1 Apotex Company Information
  45. 4.8.2 Apotex Business Overview
  46. 4.8.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  48. 4.8.5 Apotex Recent Developments
5 Global Amyotrophic Lateral Sclerosis (ALS) Market Scenario by Region
  1. 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021-2032
  3. 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021-2026
  4. 5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2027-2032
  5. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2021-2032
  6. 5.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2021-2026
  7. 5.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2027-2032
  8. 5.4 North America Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
  9. 5.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  11. 5.4.3 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
  16. 5.5.1 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  18. 5.5.3 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
  41. 5.7.1 South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  43. 5.7.3 South America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  2. 6.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  5. 6.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  2. 7.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  5. 7.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Amyotrophic Lateral Sclerosis (ALS) Value Chain Analysis
  2. 8.1.1 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
  5. 8.2 Amyotrophic Lateral Sclerosis (ALS) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
  8. 8.2.3 Amyotrophic Lateral Sclerosis (ALS) Customers
9 Global Amyotrophic Lateral Sclerosis (ALS) Analyzing Market Dynamics
  1. 9.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
  2. 9.2 Amyotrophic Lateral Sclerosis (ALS) Industry Drivers
  3. 9.3 Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges
  4. 9.4 Amyotrophic Lateral Sclerosis (ALS) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst